[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @OncBrothers Oncology Brothers Oncology Brothers posts on X about matterhorn, breast cancer, approved, os the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1424530007574122497/interactions)  - X Week XXXXXX +241% - X Month XXXXXXX +141% - X Months XXXXXXX -XXXX% - X Year XXXXXXX +55% ### Mentions: XX [#](/creator/twitter::1424530007574122497/posts_active)  ### Followers: XXXXXX [#](/creator/twitter::1424530007574122497/followers)  - X Week XXXXXX +1.20% - X Month XXXXXX +2.60% - X Months XXXXXX +14% - X Year XXXXXX +31% ### CreatorRank: XXXXXXX [#](/creator/twitter::1424530007574122497/influencer_rank)  ### Social Influence [#](/creator/twitter::1424530007574122497/influence) --- **Social category influence** [travel destinations](/list/travel-destinations) XXXXX% **Social topic influence** [matterhorn](/topic/matterhorn) #11, [breast cancer](/topic/breast-cancer) 6.9%, [approved](/topic/approved) 6.9%, [os](/topic/os) 6.9%, [events](/topic/events) 3.45%, [pts](/topic/pts) #59, [$fro](/topic/$fro) XXXX% **Top accounts mentioned or mentioned by** [@kennakoehler](/creator/undefined) [@oncoalert](/creator/undefined) [@myesmo](/creator/undefined) [@drchoueiri](/creator/undefined) [@oncupdates](/creator/undefined) [@cdanicas](/creator/undefined) [@annalsoncology](/creator/undefined) [@myriamchalabi](/creator/undefined) [@ugrewalmd](/creator/undefined) [@drjonasanilsson](/creator/undefined) [@usfda](/creator/undefined) [@dryakupergun](/creator/undefined) [@gimedonc](/creator/undefined) [@pgrivasmdphd](/creator/undefined) [@erman_akkus](/creator/undefined) [@dryukselurun](/creator/undefined) [@net_connectinfo](/creator/undefined) [@suyogcancer](/creator/undefined) [@pauljil](/creator/undefined) [@g_mountzios](/creator/undefined) **Top assets mentioned** [Frontline Ltd. (FRO)](/topic/$fro) ### Top Social Posts [#](/creator/twitter::1424530007574122497/posts) --- Top posts by engagements in the last XX hours "Treatment Algorithm: the current Rx landscape of CML with @GCC_Cortes ✅ Work-up ✅ Rx Options/Sequencing ✅ Monitoring CML & NGS ✅ AEs & Dose optimization Full discussion - - Also on Oncology Brothers podcast #MedTwitter #OncTwitter @OncUpdates" [X Link](https://x.com/OncBrothers/status/1977747257043603637) [@OncBrothers](/creator/x/OncBrothers) 2025-10-13T14:44Z 19.2K followers, 16.2K engagements "1. #POSITIVE: ET interruption to attempt pregnancy after breast cancer. - 5yr BCFI: XXXX% (vs. XXXX% in SOFT/TEXT) - 5yr DRFI: XXX% (vs. XXX% in SOFT/TEXT) Temp interruption of ET for 🤰did NOT breast ca events at 5yr follow-up 3/12" [X Link](https://x.com/OncBrothers/status/1979229766407291146) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 2538 engagements "2. #monarchE: Adj Abemaciclib (approved in Oct 2021) for high risk HR+ LN+ breast cancer 150mg BID + ET for X yrs. - 7yr IDFS: XXXX% vs. XXXX% - 7yr DRFS: XX% vs. XXXX% OS: XXXX% risk of death (HR: 0.84). X% delta in ITT OS 4/12" [X Link](https://x.com/OncBrothers/status/1979229772598083769) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 1826 engagements "3. #NATALEE: Adj #Ribociclib (approved in Sept 2024) in HR+ breast cancer (Stg IIA - III) 400mg daily (3wks on 1wk off) for 3yrs. - 5yr IDFS: XXXX% vs. XX% - OS immature positive trend (HR: 0.80) 5/12" [X Link](https://x.com/OncBrothers/status/1979229779288059905) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 1733 engagements "Gyn: X. #KEYNOTEB96: Ovarian Ca GI: X. #PEGASUS: ctDNA guided in Colon Ca X. ICI in dMMR Colon Ca X. #COMPETE: 177Lu-edotreotide GEP-NETs Lung: XX. #MDTBridge: Surg + Adj Durva vs. CRT Durva NSCLC H&N: XX. #CompARE: 🥪 approach w/ Durva vs. CRT 2/13" [X Link](https://x.com/OncBrothers/status/1979594583547039809) [@OncBrothers](/creator/x/OncBrothers) 2025-10-18T17:05Z 19.2K followers, 1104 engagements "3. #EMBARK: Enzalutamide in high risk biochemical recurrent Prostate Ca vs. ADT alone - mOS with Enzalutamide + ADT improved - 8yr mOS XXXX% vs. XXXX% (HR: 0.60) - Enza alone is not superior to ADT alone in OS 5/11" [X Link](https://x.com/OncBrothers/status/1979982740662407173) [@OncBrothers](/creator/x/OncBrothers) 2025-10-19T18:47Z 19.2K followers, XXX engagements "4. #CAPItello281: PhIII Abi + ADT +/- Capivasertib (approved for PIK3/AKT/PTEN in breast cancer - Nov 2023) in PTEN deficient de-novo mHSPC: - Median rPFS XXXX vs 25.7mos (HR: 0.81) - OS immature - AEs: Rash Hyperglycemia and diarrhea 6/11" [X Link](https://x.com/OncBrothers/status/1979982785600164166) [@OncBrothers](/creator/x/OncBrothers) 2025-10-19T18:47Z 19.2K followers, XXX engagements "1. #DESTINYBreast11: PhIII NeoAdj TDXd +/- THP vs. ddAC-THP in high risk Her2+ locally advanced early breast cancer: - pCR (67.3% vs. 56.3%) - EFS favoring TDXd (HR: 0.56) - ILD: XXX% vs.5.1 % 3/13" [X Link](https://x.com/OncBrothers/status/1979594592615100773) [@OncBrothers](/creator/x/OncBrothers) 2025-10-18T17:05Z 19.2K followers, XXX engagements "2. #DESTINYBreast05: PhIII TDXd vs. TDM1 in high risk (inoperable or LN+) residual disease after NeoAdj chemo for Her2+ Breast Cancer: - DFS & iDFS w/ TDXd (HR: XXXX in both end points). - ILD: XXX% vs. XXX% - New SoC/option for that very high risk pt 4/13" [X Link](https://x.com/OncBrothers/status/1979594596163432887) [@OncBrothers](/creator/x/OncBrothers) 2025-10-18T17:05Z 19.2K followers, 1983 engagements "3. #evERA Breast Cancer: PhIII Giredestrant (oral ER antagonist + degrader) + everolimus vs. ET + everolimus in HR+ after CDK4/6i: - mPFS 10mos vs 5.5mos (HR: 0.38) in ESR1m pts - OS immature (HR: 0.62) - Combos to likely become SoC for ESR1m 5/13" [X Link](https://x.com/OncBrothers/status/1979594603608101195) [@OncBrothers](/creator/x/OncBrothers) 2025-10-18T17:05Z 19.2K followers, 1827 engagements "8. #ALBAN: PhIII BCG + Atezolizumab vs. BCG alone in BCG naive HR-NMIBC - Negative study - No significant improvement in EFS - But POTOMAC 👇👇 is positive 10/12" [X Link](https://x.com/OncBrothers/status/1979229812649583060) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 1145 engagements "4. #VIKTROIA1: PhIII Gedatolisib (IV PI3K/mTORi) + Fulv +/- Palbo vs. Fulv in HR+ after CdK4/6i - mPFS 9.3mos vs. 2.0mos triplet vs. Fulvestrant in WT (Fulv alone is not what we do today in our practice) - Main AEs were Gr1/2. Hyperglycemia XXX% and diarrhea 16.9%. 6/13" [X Link](https://x.com/OncBrothers/status/1979594613154312439) [@OncBrothers](/creator/x/OncBrothers) 2025-10-18T17:05Z 19.2K followers, 1805 engagements "5. #KEYNOTE905: PeriOP EV + Pembro in cis-ineligible MIBC followed by postOP EV + Pembro: - EFS At 2yrs: XXXX% vs. XXXX% - EFS HR: XXXX - OS at 2yrs: XXXX% vs. XXXX (HR: 0.50) - We will now have KN905 and NIAGARA as our options for MIBC 7/13" [X Link](https://x.com/OncBrothers/status/1979594620263633355) [@OncBrothers](/creator/x/OncBrothers) 2025-10-18T17:05Z 19.2K followers, XXX engagements "We have seen similar trends for for Her2 driven disease in bucket approval studies for TDXd. This is so important to keep in mind when treating our Her2+ breast cancer patients. Excellent work @dr_yakupergun et al 👏🙏" [X Link](https://x.com/OncBrothers/status/1979874919220683145) [@OncBrothers](/creator/x/OncBrothers) 2025-10-19T11:38Z 19.2K followers, 5698 engagements "Wishing everyone celebrating a very Happy Diwali 🙏🏽🙏🏽" [X Link](https://x.com/OncBrothers/status/1980256748138016962) [@OncBrothers](/creator/x/OncBrothers) 2025-10-20T12:56Z 19.2K followers, 2946 engagements "6. #NADINA: Ph III NeoAdj Ipi/Nivo vs. Adj Nivo in Stg III melanoma. - NeoAdj Ipi/Nivo with improved EFS (HR: 0.40) and MFS (HR: 0.43) - Gr X AEs in XX% vs. XX% 8/10" [X Link](https://x.com/OncBrothers/status/1980325531842400618) [@OncBrothers](/creator/x/OncBrothers) 2025-10-20T17:29Z 19.2K followers, XXX engagements "6. HER2+ NSCLC: #SOHO01 & #BeamionLung01. 2TKIs: - Sevabertinib ORR XX% (in pretreated) and XX% in Rx naive. Pending @US_FDA approval. - Zongertinib ORR XX% and DCR: XX% (in Rx naive). Approved in Aug 2025 after systemic chemo. 8/12" [X Link](https://x.com/OncBrothers/status/1979229799471042906) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 1476 engagements "7. #MATTERHORN: Ph III Durvalumab + FLOT✂Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - Improved OS in all comers (HR: 0.78) - mOS at 3yrs: XXXX% vs. XXXX% - This is now the SoC since its initial presentation at @ASCO - What about PDL1 negative 🤔🤔 9/12" [X Link](https://x.com/OncBrothers/status/1979229805687042290) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 1963 engagements "2 wks to #ESMO25 Heres a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 - #IMVigor011 - #PSMAddition - #MDTBridge #OncTwitter @myESMO @OncoAlert" [X Link](https://x.com/OncBrothers/status/1974460748945608742) [@OncBrothers](/creator/x/OncBrothers) 2025-10-04T13:05Z 19.2K followers, 26K engagements "Day X #ESMO25 Highlights: Breast Ca: X. #POSITIVE 🤰 outcomes X. #monarchE HR+ Adj Abema X. #NATALEE HR+ Adj Ribo Lung Ca: X. #NorthStar Local Rx in mEGFR X. #FLAURA2 Chemo + Osi in mEGFR X. #SOHO01 & #BeamionLung01 HER2+ NSCLC 1/12 #OncTwitter @myESMO @OncUpdates" [X Link](https://x.com/OncBrothers/status/1979229758278795690) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 20.5K engagements "GI Malignancy: X. #MATTERHORN FLOT-Durva in resectable Gastric/GEJ GU: X. #ALBAN: Atezo + BCG in HR-NMIBC X. #POTOMAC: Durva + BCG in HR-NMIBC Supp/Pall Onc: XX. #REaCTHold: De-escalating 🦴 modifying agents 2/12" [X Link](https://x.com/OncBrothers/status/1979229760782770387) [@OncBrothers](/creator/x/OncBrothers) 2025-10-17T16:55Z 19.2K followers, 2151 engagements "5. #IMvigor011: PhIII adj atezolizumab in high-risk MIBC who are ctDNA+ - mDFS XXX vs. XXX mos (HR: 0.64) - mOS XXXX vs. XXXX mos (HR: 0.59) - If using adj Rx thisll be the new SoC. Can we extrapolate this to KN905 and NIAGARA @apolo_andrea @PGrivasMDPhD 7/10" [X Link](https://x.com/OncBrothers/status/1980325524250779791) [@OncBrothers](/creator/x/OncBrothers) 2025-10-20T17:29Z 19.2K followers, 4204 engagements "If/when D-FLOT (based off #MATTERHORN) was to become available and approved for all comers for PDL1 negative ( 1%) if otherwise eligible do you plan to add Durva @UGrewalMD @GIMedOnc @GIcancerDoc @rutikamehtaMD @KlempnerSam @YJanjigianMD #aoncTwitter" [X Link](https://x.com/OncBrothers/status/1980990045952807006) [@OncBrothers](/creator/x/OncBrothers) 2025-10-22T13:30Z 19.2K followers, 3594 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@OncBrothers Oncology Brothers
Oncology Brothers posts on X about matterhorn, breast cancer, approved, os the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +241%
- X Month XXXXXXX +141%
- X Months XXXXXXX -XXXX%
- X Year XXXXXXX +55%
Mentions: XX #
Followers: XXXXXX #
- X Week XXXXXX +1.20%
- X Month XXXXXX +2.60%
- X Months XXXXXX +14%
- X Year XXXXXX +31%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence travel destinations XXXXX%
Social topic influence matterhorn #11, breast cancer 6.9%, approved 6.9%, os 6.9%, events 3.45%, pts #59, $fro XXXX%
Top accounts mentioned or mentioned by @kennakoehler @oncoalert @myesmo @drchoueiri @oncupdates @cdanicas @annalsoncology @myriamchalabi @ugrewalmd @drjonasanilsson @usfda @dryakupergun @gimedonc @pgrivasmdphd @erman_akkus @dryukselurun @net_connectinfo @suyogcancer @pauljil @g_mountzios
Top assets mentioned Frontline Ltd. (FRO)
Top Social Posts #
Top posts by engagements in the last XX hours
"Treatment Algorithm: the current Rx landscape of CML with @GCC_Cortes ✅ Work-up ✅ Rx Options/Sequencing ✅ Monitoring CML & NGS ✅ AEs & Dose optimization Full discussion - - Also on Oncology Brothers podcast #MedTwitter #OncTwitter @OncUpdates"
X Link @OncBrothers 2025-10-13T14:44Z 19.2K followers, 16.2K engagements
"1. #POSITIVE: ET interruption to attempt pregnancy after breast cancer. - 5yr BCFI: XXXX% (vs. XXXX% in SOFT/TEXT) - 5yr DRFI: XXX% (vs. XXX% in SOFT/TEXT) Temp interruption of ET for 🤰did NOT breast ca events at 5yr follow-up 3/12"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 2538 engagements
"2. #monarchE: Adj Abemaciclib (approved in Oct 2021) for high risk HR+ LN+ breast cancer 150mg BID + ET for X yrs. - 7yr IDFS: XXXX% vs. XXXX% - 7yr DRFS: XX% vs. XXXX% OS: XXXX% risk of death (HR: 0.84). X% delta in ITT OS 4/12"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 1826 engagements
"3. #NATALEE: Adj #Ribociclib (approved in Sept 2024) in HR+ breast cancer (Stg IIA - III) 400mg daily (3wks on 1wk off) for 3yrs. - 5yr IDFS: XXXX% vs. XX% - OS immature positive trend (HR: 0.80) 5/12"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 1733 engagements
"Gyn: X. #KEYNOTEB96: Ovarian Ca GI: X. #PEGASUS: ctDNA guided in Colon Ca X. ICI in dMMR Colon Ca X. #COMPETE: 177Lu-edotreotide GEP-NETs Lung: XX. #MDTBridge: Surg + Adj Durva vs. CRT Durva NSCLC H&N: XX. #CompARE: 🥪 approach w/ Durva vs. CRT 2/13"
X Link @OncBrothers 2025-10-18T17:05Z 19.2K followers, 1104 engagements
"3. #EMBARK: Enzalutamide in high risk biochemical recurrent Prostate Ca vs. ADT alone - mOS with Enzalutamide + ADT improved - 8yr mOS XXXX% vs. XXXX% (HR: 0.60) - Enza alone is not superior to ADT alone in OS 5/11"
X Link @OncBrothers 2025-10-19T18:47Z 19.2K followers, XXX engagements
"4. #CAPItello281: PhIII Abi + ADT +/- Capivasertib (approved for PIK3/AKT/PTEN in breast cancer - Nov 2023) in PTEN deficient de-novo mHSPC: - Median rPFS XXXX vs 25.7mos (HR: 0.81) - OS immature - AEs: Rash Hyperglycemia and diarrhea 6/11"
X Link @OncBrothers 2025-10-19T18:47Z 19.2K followers, XXX engagements
"1. #DESTINYBreast11: PhIII NeoAdj TDXd +/- THP vs. ddAC-THP in high risk Her2+ locally advanced early breast cancer: - pCR (67.3% vs. 56.3%) - EFS favoring TDXd (HR: 0.56) - ILD: XXX% vs.5.1 % 3/13"
X Link @OncBrothers 2025-10-18T17:05Z 19.2K followers, XXX engagements
"2. #DESTINYBreast05: PhIII TDXd vs. TDM1 in high risk (inoperable or LN+) residual disease after NeoAdj chemo for Her2+ Breast Cancer: - DFS & iDFS w/ TDXd (HR: XXXX in both end points). - ILD: XXX% vs. XXX% - New SoC/option for that very high risk pt 4/13"
X Link @OncBrothers 2025-10-18T17:05Z 19.2K followers, 1983 engagements
"3. #evERA Breast Cancer: PhIII Giredestrant (oral ER antagonist + degrader) + everolimus vs. ET + everolimus in HR+ after CDK4/6i: - mPFS 10mos vs 5.5mos (HR: 0.38) in ESR1m pts - OS immature (HR: 0.62) - Combos to likely become SoC for ESR1m 5/13"
X Link @OncBrothers 2025-10-18T17:05Z 19.2K followers, 1827 engagements
"8. #ALBAN: PhIII BCG + Atezolizumab vs. BCG alone in BCG naive HR-NMIBC - Negative study - No significant improvement in EFS - But POTOMAC 👇👇 is positive 10/12"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 1145 engagements
"4. #VIKTROIA1: PhIII Gedatolisib (IV PI3K/mTORi) + Fulv +/- Palbo vs. Fulv in HR+ after CdK4/6i - mPFS 9.3mos vs. 2.0mos triplet vs. Fulvestrant in WT (Fulv alone is not what we do today in our practice) - Main AEs were Gr1/2. Hyperglycemia XXX% and diarrhea 16.9%. 6/13"
X Link @OncBrothers 2025-10-18T17:05Z 19.2K followers, 1805 engagements
"5. #KEYNOTE905: PeriOP EV + Pembro in cis-ineligible MIBC followed by postOP EV + Pembro: - EFS At 2yrs: XXXX% vs. XXXX% - EFS HR: XXXX - OS at 2yrs: XXXX% vs. XXXX (HR: 0.50) - We will now have KN905 and NIAGARA as our options for MIBC 7/13"
X Link @OncBrothers 2025-10-18T17:05Z 19.2K followers, XXX engagements
"We have seen similar trends for for Her2 driven disease in bucket approval studies for TDXd. This is so important to keep in mind when treating our Her2+ breast cancer patients. Excellent work @dr_yakupergun et al 👏🙏"
X Link @OncBrothers 2025-10-19T11:38Z 19.2K followers, 5698 engagements
"Wishing everyone celebrating a very Happy Diwali 🙏🏽🙏🏽"
X Link @OncBrothers 2025-10-20T12:56Z 19.2K followers, 2946 engagements
"6. #NADINA: Ph III NeoAdj Ipi/Nivo vs. Adj Nivo in Stg III melanoma. - NeoAdj Ipi/Nivo with improved EFS (HR: 0.40) and MFS (HR: 0.43) - Gr X AEs in XX% vs. XX% 8/10"
X Link @OncBrothers 2025-10-20T17:29Z 19.2K followers, XXX engagements
"6. HER2+ NSCLC: #SOHO01 & #BeamionLung01. 2TKIs: - Sevabertinib ORR XX% (in pretreated) and XX% in Rx naive. Pending @US_FDA approval. - Zongertinib ORR XX% and DCR: XX% (in Rx naive). Approved in Aug 2025 after systemic chemo. 8/12"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 1476 engagements
"7. #MATTERHORN: Ph III Durvalumab + FLOT✂Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - Improved OS in all comers (HR: 0.78) - mOS at 3yrs: XXXX% vs. XXXX% - This is now the SoC since its initial presentation at @ASCO - What about PDL1 negative 🤔🤔 9/12"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 1963 engagements
"2 wks to #ESMO25 Heres a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 - #IMVigor011 - #PSMAddition - #MDTBridge #OncTwitter @myESMO @OncoAlert"
X Link @OncBrothers 2025-10-04T13:05Z 19.2K followers, 26K engagements
"Day X #ESMO25 Highlights: Breast Ca: X. #POSITIVE 🤰 outcomes X. #monarchE HR+ Adj Abema X. #NATALEE HR+ Adj Ribo Lung Ca: X. #NorthStar Local Rx in mEGFR X. #FLAURA2 Chemo + Osi in mEGFR X. #SOHO01 & #BeamionLung01 HER2+ NSCLC 1/12 #OncTwitter @myESMO @OncUpdates"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 20.5K engagements
"GI Malignancy: X. #MATTERHORN FLOT-Durva in resectable Gastric/GEJ GU: X. #ALBAN: Atezo + BCG in HR-NMIBC X. #POTOMAC: Durva + BCG in HR-NMIBC Supp/Pall Onc: XX. #REaCTHold: De-escalating 🦴 modifying agents 2/12"
X Link @OncBrothers 2025-10-17T16:55Z 19.2K followers, 2151 engagements
"5. #IMvigor011: PhIII adj atezolizumab in high-risk MIBC who are ctDNA+ - mDFS XXX vs. XXX mos (HR: 0.64) - mOS XXXX vs. XXXX mos (HR: 0.59) - If using adj Rx thisll be the new SoC. Can we extrapolate this to KN905 and NIAGARA @apolo_andrea @PGrivasMDPhD 7/10"
X Link @OncBrothers 2025-10-20T17:29Z 19.2K followers, 4204 engagements
"If/when D-FLOT (based off #MATTERHORN) was to become available and approved for all comers for PDL1 negative ( 1%) if otherwise eligible do you plan to add Durva @UGrewalMD @GIMedOnc @GIcancerDoc @rutikamehtaMD @KlempnerSam @YJanjigianMD #aoncTwitter"
X Link @OncBrothers 2025-10-22T13:30Z 19.2K followers, 3594 engagements